Tafluprost acid

• UNSPSC Description:

  Tafluprost acid (AFP-172), an active metabolic form of Tafluprost, is a selective prostanoid FP receptor agonist. Tafluprost acid shows a high affinity for human prostanoid FP receptor with Ki and EC50 values of 0.4 nM and 0.53 nM, respectively. Tafluprost acid has 126 times weaker binding affinity for prostanoid EP3 receptor (IC50=67 nM) than for the prostanoid FP receptor. Tafluprost acid can be used in the research of glaucoma[1][2][3].

• Target Antigen:

  Drug Metabolite; Prostaglandin Receptor

• Type:

  Reference compound

• Related Pathways:

  GPCR/G Protein;Metabolic Enzyme/Protease

• Applications:

  Metabolism-sugar/lipid metabolism

• Field of Research:

  Endocrinology; Neurological Disease; Cardiovascular Disease

• Assay Protocol:

  https://www.medchemexpress.com/tafluprost-acid.html

• Purity:

  99.80

• Solubility:

  DMSO : 100 mg/mL (ultrasonic)

• Smiles:

  O[C@H]([C@@H]1C/C=C\CCCC(O)=O)C[C@H]([C@@H]1/C=C/C(F)(COC2=CC=CC=C2)F)O

• Molecular Weight:

  410.45

• References & Citations:

  [1]Takagi Y, et al. Pharmacological characteristics of AFP-168 (tafluprost), a new prostanoid FP receptor agonist, as an ocular hypotensive drug. Exp Eye Res. 2004 Apr;78(4):767-76.|[2]Taketani Y, et al. Activation of the prostanoid FP receptor inhibits adipogenesis leading to deepening of the upper eyelid sulcus in prostaglandin-associated periorbitopathy. Invest Ophthalmol Vis Sci. 2014 Mar 4;55(3):1269-76.|[3]Roh YJ, et al. Effects of AFP-172 on COX-2-induced angiogenic activities on human umbilical vein endothelial cells. Graefes Arch Clin Exp Ophthalmol. 2012 Dec;250(12):1765-75.|[4]Fuwa M, et al. Advantages of Efficacy and Safety of Fixed-Dose Tafluprost/Timolol Combination Over Fixed-Dose Latanoprost/Timolol Combination. PLoS One. 2016 Jul 6;11(7):e0158797.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  4°C (Powder, protect from light)

• Clinical Information:

  Launched

• CAS Number:

  209860-88-8